Related Experiment Videos
Antenatal dexamethasone and decreased severity of retinopathy of prematurity
R D Higgins1, A L Mendelsohn, M J DeFeo
1Department of Pediatrics, New York University Medical Center and Bellevue Hospital Center, New York City, USA. higginsr1@gunet.georgetown.edu
Insights
Antenatal dexamethasone exposure significantly reduced the risk of severe retinopathy of prematurity (ROP) in premature infants. This finding highlights a potential protective factor for ROP development in high-risk newborns.
Area of Science:
- Neonatal Ophthalmology
- Perinatal Medicine
- Public Health
Background:
- Retinopathy of prematurity (ROP) is a significant cause of visual impairment in premature infants.
- Identifying modifiable risk factors is crucial for ROP prevention strategies.
Purpose of the Study:
- To investigate risk factors associated with ROP development in an urban infant population.
- Specifically, to assess the impact of antenatal dexamethasone exposure on ROP incidence.
Main Methods:
- An observational cohort study was conducted at a regional perinatal referral center.
- Data from 63 premature infants (birth weight < 1250 g) were analyzed, including birth weight, gestational age, and maternal/neonatal factors.
- ROP screening results were correlated with antenatal dexamethasone exposure and other clinical variables.
Main Results:
- Infants exposed to antenatal dexamethasone had significantly lower rates of stage 2 or higher ROP (8.7% vs. 35%).
- Birth weight, gestational age, respiratory distress syndrome, bronchopulmonary dysplasia, and patent ductus arteriosus were also associated with ROP.
- After adjusting for confounders, antenatal dexamethasone remained significantly associated with decreased ROP risk (adjusted OR, 0.14).
Conclusions:
- Antenatal dexamethasone administration appears to be a protective factor against the development of stage 2 or higher ROP.
- The protective association was particularly strong in infants born between 24 to 28 weeks of gestation.
Objective:
To assess risk factors associated with the development of retinopathy of prematurity (ROP) in an urban population.
Design:
Observational cohort study.
Setting:
Bellevue Hospital Center, a regional perinatal referral center in New York City.
Patients:
Surviving inborn infants with birth weight less than 1250 g undergoing an ophthalmologic screening examination.
Main Outcome Measures:
Screening examination results for ROP were obtained. Additional data included birth weight, gestational age, maternal factors, and common neonatal diagnoses and exposures.
Results:
Sixty-three infants were included in the analysis. Mean +/- SD birth weight was 981+/-179 g and mean gestational age was 27.8+/-2.4 weeks. Infants whose mothers received antenatal dexamethasone developed significantly less ROP that was stage 2 or higher than infants without a history of antenatal dexamethasone exposure--8.7% (2/23) vs 35% (14/40), respectively (P=.04). Birth weight, gestational age, respiratory distress syndrome, bronchopulmonary dysplasia, and patent ductus arteriosus were also significantly associated with the development of ROP that was stage 2 or higher. After controlling for these confounders by multiple logistic regression analysis, antenatal dexamethasone administration was associated with a significantly decreased risk of development of ROP stage 2 or higher (adjusted odds ratio [OR], 0.14; 95% confidence interval [CI], 0.02-0.93). The association was stronger when the analysis was restricted to the 36 infants who were 24 to 28 weeks of gestational age (adjusted OR, 0.02; 95% CI, 0.00-0.76).
Conclusion:
Antenatal dexamethasone administration appears to be associated with a decreased incidence of development of ROP of stage 2 or higher in this urban population.